Australia's most trusted
source of pharma news
Friday, 05 December 2025
Posted 5 December 2025 AM
An appeal to save patent protection for a $57 million market has been rejected, but for different reasons than the original decision, which could allow other patent term extensions to be challenged.
In February this year Justice Kylie Downes of the Federal Court ruled that the patent term extension (PTE) which extended patent protection of Otsuka's Abilify Maintena to 25 July 2029 had been wrongly granted, meaning the patent expired on 18 October 2024.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.